Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
744 Phase 1b/2, multicenter dose escalation and expansion... | ResearchHub
Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
744 Phase 1b/2, multicenter dose escalation and expansion study of muzastotug (ADG126, a masked anti-CTLA-4 SAFEbody®) in combination with pembrolizumab in advanced/metastatic MSS CRC
0
Authors
Daneng Li
17 more
Daneng Li
•
Sun Kim
15 more
•
Manish Patel
Published
November 1, 2024
Paper
Conversation
0
Reviews
0
Bounties
0
Abstract
Supporters
Support the authors with ResearchCoin
Tip RSC
Journal
Regular and Young Investigator Award Abstracts
Topics
Medicine
Cancer Oncology
Immunology
Internal Medicine
Pembrolizumab
Show all topics
DOI
10.1136/jitc-2024-sitc2024.0744
